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Abstract
The growth hormone (GH)–insulin-like growth factor-1 (IGF-1) axis is dramatically altered in patients with anorexia nervosa (AN). The aim
of the present study was to investigate whether GH and IGF-1 could be predictors of outcome in patients with a restrictive form of AN.
Blood levels of GH, IGF-1, adipocytokines, ghrelin, insulin, glucose, and sex and thyroid hormones were measured in eleven women inpa-
tients with AN and in ten healthy women controls. Three stages were compared during refeeding: admission (T0), when BMI reached
16 kg/m2 (T1) and at discharge when BMI reached 17·5 kg/m2 (T2). Clinical status was assessed 6 months after discharge from hospital
(T3), and remission was defined by the maintenance of a BMI $17·5 kg/m2. AN patients in remission (AN-R; n 6) had significantly
higher GH levels at admission than those who relapsed (AN-NR; n 5) (P,0·05). During refeeding (D ¼ T2 2 T0), the AN-R group differed
from the AN-NR group only by both GH level decrease (P,0·05) and BMI increase (P,0·05). In multiple regression analysis, DGH was
associated negatively and significantly and Dleptin and Dbody fat mass levels were associated positively and significantly with BMI at T3
and explained 88 % of its variability (r 2 0·88, P,0·05). The present study suggests that a low GH level at admission and the absence of its
decrease after weight recovery could predict short-term relapse in women suffering from a restrictive form of AN.
Key words: Anorexia nervosa: Growth hormone: Insulin-like growth factor-1: Outcomes
Anorexia nervosa (AN) is an eating disorder caused by
voluntary restriction of energy intake, intensive physical
exercise and/or purging behaviours, and is characterised by
weight loss, mainly at the expense of adipose tissue(1,2).
These behaviours lead to multiple endocrine abnormalities
commonly associated with starvation, including high ghrelin
levels, hypogonadotropic hypogonadism and adipocytokine
disturbances(3,4). Most of these anomalies are corrected with
the recovery of normal nutritional conditions(5).
Several studies have shown that the growth hormone
(GH)–insulin-like growth factor-1 (IGF-1) axis was dramati-
cally altered in patients with AN(6,7). But, although Argente
et al.(6) have discerned two different groups of anorexic
patients, one group having hypersecretion of GH and one
group with hyposecretion of GH, they were unable to
distinguish these two groups regarding either physical or
psychological parameters at the time of diagnosis or during
the recuperation period.
In the present study, the main objective was to investigate if
GH and IGF-1 levels could represent prognostic factors of out-
come in restrictive AN. To test this hypothesis, we performed a
prospective study on a homogeneous group of eleven patients
suffering from a severe pure restrictive form of AN and sub-
mitted to the same standardised inpatient protocol treatment.
GH and IGF-1 levels, as well as hormone and adipocytokine
profiles, insulin sensitivity, body composition and energy
expenditure, were assessed at admission and at various
stages of weight recuperation.
*Corresponding author: R. Vale´ro, fax þ33 4 91 38 65 99, email rvalero@mail.ap-hm.fr
Abbreviations: AN, anorexia nervosa; AN-NR, anorexia nervosa-not in remission; AN-R, anorexia nervosa-remission; BFM, body fat mass; DSM-IV,
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; FGF-21, fibroblast growth factor-21; GH, growth hormone; HOMA-IR,
homeostasis model assessment-insulin resistance; IGF-1, insulin-like growth factor-1; T0, admission (baseline); T1, BMI reached 16 kg/m2; T2, discharge
when BMI reached 17·5 kg/m2; T3, assessment at 6 months after discharge.
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The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human patients were approved by the Research
Ethics Board of Aix-Marseille University and all subjects gave
verbal informed consent. Verbal consent was witnessed and
formally recorded. A total of eleven women suffering from
AN were recruited in our department of nutrition. All subjects
met the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) criteria for the restrictive form of AN.
This population was homogeneously selected as every patient
included in this series suffered from the short-duration (12·2
(SEM 5·0) weeks) and active (BMI loss rate: 20·2 (SEM
0·03) kg/m2 per week) restrictive type of AN. Patients with
relapsing AN or exhibiting binge eating–purging behaviours
were excluded. The patients were referred to the inpatient
unit due to the presence of at least one of the following con-
ditions: life-threatening medical condition due to severe mal-
nutrition, incapacity to reach weight objectives during
ambulatory care or marked suicidal ideation. None of the
patients used oral contraception for several weeks before
the hospitalisation in our department. All patients were treated
by a single team from the department of nutrition according to
a structured inpatient protocol combining medical, nutritional
and psychiatric supports based on widely accepted standards
of practice(8,9). Treatment was based on a weight contract
(progressive return to near-normal BMI, i.e. $17·5 kg/m2)
and consisted of medical supervision, nutritional support by
a dietitian, mixed cognitive behavioural and analytical psy-
chotherapy sessions and art therapy, both performed twice a
week. The standardised feeding protocol consisted of a pro-
gressive increment of energy intake from 3350 to 8370 kJ/d.
Methods
Patients were studied at three stages of care: at admission (T0),
when BMI reached 16 kg/m2 (T1), and at discharge, when BMI
reached 17·5 kg/m2 (T2). The diet of each patient was esti-
mated by a dietitian at admission (T0) before refeeding. Clini-
cal status was assessed 6 months after discharge from hospital
(T3). Short-term remission was defined by the maintenance of
a BMI $17·5 kg/m2 at 6 months after discharge. A BMI
$17·5 kg/m2 was chosen to define remission because the
diagnostic criteria for AN from the DSM-IV include a BMI
#17·5 kg/m2 (10). The weight achieved to reach a BMI
$17·5 kg/m2 at discharge was defined as the ‘target weight’
in the present study. In all, six patients exhibited remission
(AN-R group) and five patients were characterised by a
quick relapse, being unable to maintain their weight objective
(AN-NR group). It was impossible to take into account ‘the
healthy weight’ defined by the weight at the loss of menstrua-
tion because most of the patients (four of six patients in the
remission group (AN-R group) and four of five in the not in
remission group (AN-NR group)) were taking oral oestropro-
gestogenic treatment. In addition, ten normal-weight healthy
women were recruited as controls after a medical interview
and a physical examination by a physician specialised in
nutrition. None of them had any history of eating disorders
or other psychiatric illness.
Blood samples were obtained between 07.00 and 08.00
hours after an overnight fast. Plasma glucose was measured
using the hexokinase oxidase method (Beckman Coulterw)
and plasma insulin levels were determined by electrochemilu-
minescence (Roche Diagnosticsw). Insulin resistance was esti-
mated using homeostasis model assessment-insulin resistance
(HOMA-IR ¼ fasting insulin (mIU/l) £ fasting glucose (mmol/l)/
22·5). Alanine aminotransferase and aspartate aminotrans-
ferase were determined by Synchron-CX automate (Beckman
Coulterw). GH and IGF-1 were measured using immunoradio-
metric assays (DiaSorinw). Testosterone and oestradiol were
measured by electrochemiluminescence (Roche Diagnos-
ticsw). Specific ELISA kits were used to measure serum
levels of leptin (active human leptin, DSL Systems), adipo-
nectin (Quantikine human adiponectin, R&D Systems), resistin
(Quantikine human resistin, R&D Systems) and ghrelin
(human unacylated ghrelin enzyme immunoassay kit,
Biovendor).
Body composition was assessed by dual-energy X-ray
absorptiometry (Lunar iDXA, GE Healthcare): body fat mass
(BFM), body lean mass and fat-free mass compartments
were considered. Resting energy expenditure was measured
by indirect calorimetry (Quark-RMR-Cosmedw) in the morning
after an overnight fast. Total, resting and active energy expen-
diture were evaluated using a wearable multisensor armband
(SenseWearw Pro2 Armband SWA, BodyMedia, Inc.)(11).
Statistical analysis
Statistical analysis was carried out using SPSS software (Statisti-
cal Package for the Social Sciences, Inc., version 15.0). The
results are presented as mean values with their standard
errors. The paired Wilcoxon test and the Mann–Whitney U
test were used for comparisons between groups. Spearman’s
correlation was used to test the association among anthro-
pometric, biochemical, hormonal, body composition and
energy metabolism parameters in AN patients at T0, T1 and
T2. Before the multivariate analyses, variables with skewed
distributions were logarithmically transformed to normalise
the distributions. Associations were evaluated by linear
regression and multiple interactions by stepwise regression
and by exhaustive check of all possible multivariate models.
The structure of the covariance matrix for each variable was
taken into account in all analyses to ensure the most adequate
statistical fit and power. A P,0·05 was considered statistically
significant.
Results
Comparison between control women and anorexia
nervosa women patients at admission (T0)
The mean ages of the AN patients and control subjects were
similar at admission. As expected, BMI was significantly
lower in the AN group (P,0·05) (Table 1) .

















Plasma GH and serum ghrelin levels were higher in AN
patients compared with controls (P,0·05 for both). Plasma
levels of IGF-1, oestradiol, free tri-iodothyronine, leptin and
adiponectin were significantly lower in patients with AN com-
pared with control subjects (P,0·05 for all). Plasma levels of
glucose, insulin and HOMA-IR were significantly lower in
patients with AN than in control subjects (P,0·05 for all).
Comparison between admission (T0) and first stage of
refeeding (T1) in anorexia nervosa patients
The first stage of refeeding (T1) was reached after a mean of
14·1 (SEM 3·3) weeks of hospitalisation (Table 1). As expected,
an improvement in body composition was observed after this
first period of refeeding. BFM and body lean mass both
increased significantly and resting energy expenditure, active
energy expenditure and total energy expenditure also
increased significantly during this stage (P,0·05 for all).
A significant decrease in GH, ghrelin and testosterone levels
and an increase in IGF-1, free tri-iodothyronine and oestradiol
concentrations were observed (P,0·05 for all). Concerning
adipocytokine levels, a significant increase was only seen
with adiponectin (P,0·05). There was a significant increase
in glucose, insulin and HOMA-IR levels (P,0·05 for all).
In Spearman’s correlation analysis at T1, there was a signifi-
cant negative association between GH and plasma glucose
levels and between GH levels and active energy expenditure
(r 20·7, P¼0·04 and r 20·8, P¼0·02, respectively).
Comparison between first stage (T1) of refeeding and
discharge (T2) in anorexia nervosa patients
The second stage of refeeding (T2) was reached after a mean
hospitalisation of 3·7 (SEM 1·2) weeks from the first stage of
refeeding (T1) (Table 1). During this second stage, BFM
was the only body composition parameter to increase, but
non-significantly. Resting energy expenditure increased
significantly (P,0·05).
There was a significant increase in IGF-1 and leptin levels
(P,0·05 for both). Glucose and HOMA-IR levels increased
significantly (P,0·05 for both).
In Spearman’s correlation analysis at T2, plasma GH levels
were negatively and significantly associated with leptin
levels (r 20·8, P¼0·03).
Table 1. Anthropometric, biochemical, hormonal, body composition and energy metabolism parameters of control (C)
women and patients with anorexia nervosa (AN) at admission and during refeeding
(Mean values with their standard errors)
C (n 10) AN-T0 (n 11) AN-T1 (n 11) AN-T2 (n 11)
Mean SEM Mean SEM Mean SEM Mean SEM
Age (years) 24·6 0·17 21·9 0·36
BMI (kg/m2) 22·3 0·16 13·1* 0·07 16·1† 0·02 17·8‡ 0·02
ASAT (U/l) 15·4 0·42 17·2 0·53 21·1 0·34 24·2 0·24
ALAT (U/l) 22·5 0·39 28·1 0·51 26·3 0·25 27·8 0·23
Glucose (mmol/l) 4·5 0·04 3·9* 0·05 4·5† 0·03 4·9‡ 0·04
Insulin (mIU/l) 7·7 0·49 3·0* 0·24 7·3† 0·40 9·5 0·36
HOMA-IR 1·5 0·06 0·5* 0·05 1·4† 0·09 2·1‡ 0·10
GH (mIU/l) 8·7 0·65 24·5* 0·64 1·64† 0·15 1·3 0·11
IGF-1 (nmol/l 26·3 0·46 13·7* 0·75 27·2† 0·49 31·5‡ 0·63
TSH (mIU/l) 1·5 0·10 2·0 0·10 2·2 0·08 2·6 0·08
FT4 (pmol/l) 13·9 0·15 12·7 0·14 11·9 0·33 12·6 0·14
FT3 (pmol/l) 4·9 0·06 2·4* 0·11 5·0† 0·12 4·3 0·15
Oestradiol (pmol/l) 257 10·50 57·1* 4·40 154† 10·40 226 14·30
Testosterone (nmol/l) 1·03 0·04 1·6 0·07 0·9† 0·03 0·9 0·02
Adiponectin (mg/ml) 10·9 0·52 6·7* 0·37 17·1† 0·51 15·1 0·55
Resistin (ng/ml) 11·8 0·38 13·1 0·80 12·5 0·48 10·0 0·32
Leptin (ng/ml) 11·6 0·35 0·4* 0·01 3·1 0·38 8·0‡ 0·56
Ghrelin (pg/ml) 305·0 9·60 490·6* 21·2 274·5† 14·9 229·0 10·5
BFM (kg) ND 3·5 0·13 8·2† 0·19 11·8 0·14
BLM (kg) ND 32·3 0·38 37·2† 0·29 35·9 0·27
FFM (kg) ND 34·1 0·37 39·3 0·25 37·9 0·30
REE (kJ/d) ND 2840·1 66·1 4404·9† 62·8 4792·4‡ 70·3
TEE (kJ/d) ND 5314·9 80·3 6364·3† 71·9 6439·6 236·9
AEE (kJ/d) ND 419·7 40·6 865·7† 45·2 1603·7 96·2
T0, admission (baseline); T1, BMI reached 16 kg/m2; T2, discharge when BMI reached 17·5 kg/m2; ASAT, aspartate aminotransferase;
ALAT, alanine aminotransferase; HOMA-IR, homeostasis model assessment-insulin resistance; GH, growth hormone; IGF-1, insulin-like
growth factor-1; TSH, thyroid-stimulating hormone; FT4, free thyroxine; FT3, free tri-iodothyronine; BFM, body fat mass; ND, not deter-
mined; BLM, body lean mass; FFM, fat-free mass; REE, resting energy expenditure; TEE, total energy expenditure; AEE, active energy
expenditure.
* Mean value was significantly different for C from that of the AN group before refeeding (AN-T0) (P,0·05; Mann–Whitney U test or
Wilcoxon test).
† Mean value was significantly different for the first step of refeeding (AN-T1) from that of before refeeding (AN-T0) (P,0·05; Mann–
Whitney U test or Wilcoxon test).
‡ Mean value was significantly different for the first step of refeeding (AN-T1) from that of the second step of refeeding (AN-T2)
(P,0·05; Mann–Whitney U test or Wilcoxon test).

















Prediction of short-term clinical outcome
At 6 months after discharge from hospital with a BMI
$17·5 kg/m2, the AN-R group maintained this objective (BMI
18·08 (SEM 0·2) kg/m2), whereas the AN-NR group did not
(BMI 17·28 (SEM 0·2) kg/m2). At admission, there were no
differences in the total energy intake or in the nutrient
intake between the AN-R and the AN-NR groups (2495 (SEM
177) v. 2215 (SEM 134) kJ/d for total energy intake; 30·4 (SEM
2·2) v. 37·0 (SEM 4·0) g (20·6 (SEM 1·2) v. 25·6 (SEM 2·1) %) for
protein intake; 73·0 (SEM 7·9) v. 61·2 (SEM 4·9) g (46·6 (SEM
2·5) v. 49·8 (SEM 5·0) %) for carbohydrate intake; and 20·8
(SEM 1·2) v. 15·6 (SEM 2·5) g (32·8 (SEM 1·5) v. 24·4 (SEM
3·4) %) for fat intake). In univariate analysis, the AN-R group
differed from the AN-NR group at admission only by GH
levels (39·8 (SEM 1·2) v. 5·9 (SEM 0·8) mIU/l; P,0·05)
(Fig. 1(a)), but not by IGF-1 levels (14·4 (SEM 1·2) v. 13·9
(SEM 1·5) nmol/l, P¼0·65) (Fig. 1(b)) or by the other anthropo-
metric, biochemical, hormonal, body composition and energy
metabolism parameters. GH levels were higher in the AN-R
group compared with the control group, but not different
between the AN-NR and the control groups (Fig. 1(a)).
IGF-1 levels were lower in the AN-R and AN-NR groups com-
pared with the control group (Fig. 1(b)).
During refeeding, (D ¼ T2 2 T0), the AN-R group differed
from AN-NR group only by both GH level decrease (215·3
(SEM 2·10) v. 23·6 (SEM 1·84) mIU/l, P,0·05) and BMI increase
(5·6 (SEM 0·3) v. 3·8 (SEM 0·2) kg/m2; P,0·05) (Table 2). When
we compared the GH level in relation to weight at admission
(T0), at T1 and at discharge (T2), we found a higher mean
ratio in the AN-R group v. the AN-NR group at T0 (P,0·05),
but no difference at T1 and T2 between the two groups and
a significant decrease of this mean ratio only in the AN-R
group between T0 and T1 (P,0·05) and between T0 and T2
(P,0·05). The mean DGH (T2 2 T0) in relation to the ‘target
weight’ at T2 was significantly lower in the AN-R group v. the
AN-NR group (P,0·05) (Table 3). The difference in BMI increase
between the two groups was explained by a non-significant
lower BMI in the AN-R group at admission (Table 4) and by a
non-significant higher BMI in the AN-R group at discharge.
In an additional stepwise multivariate analysis of BMI at
6-month follow-up (T3), carried out for all the patients and
adjusted for (D ¼ T2 2 T0) Dglucose, Dinsulin, DHOMA-IR,
DGH, DIGF-1, DTSH, DFT4, Dfree tri-iodothyronine, Doestra-
diol, Dtestosterone, Dadiponectin, Dresistin, Dleptin, Dghrelin,
DBFM, Dbody lean mass and Dfat-free mass, we found that
DGH was associated negatively and significantly with the varia-
bility of BMI (b 20·89; P,0·05) and that Dleptin and DBFM
were associated positively and significantly with the variability
of BMI (b 0·11; P,0·05 and b 0·39; P,0·05, respectively).
Table 2. Anthropometric, biochemical, hormonal and body composition
changes during refeeding (between admission (T0) and discharge (T2))
in anorexia nervosa (AN) patients in remission (AN-R) and not in remis-
sion (AN-NR) 6 months after discharge
(Mean values with their standard errors)
AN-R (n 6) AN-NR (n 5)
DT2 2 T0† Mean SEM Mean SEM
DBMI (kg/m2) 5·6 0·30 3·8* 0·20
DGlucose (mmol/l) 1·0 0·03 1·2 0·02
DInsulin (mIU/l) 6·1 0·08 6·2 0·07
DHOMA-IR 1·5 0·03 1·6 0·07
DGH (mIU/l) 215·3 2·10 23·6* 1·84
DIGF-1 (nmol/l) 9·2 0·88 17·2 0·94
DTSH (mIU/l) 0·8 0·08 0·9 0·06
DFT4 (pmol/l) 1·6 0·23 1·4 0·66
DFT3 (pmol/l) 2·9 0·08 2·3 0·09
DOestradiol (pmol/l) 141·6 10·60 339·1 26·73
DTestosterone (nmol/l) 21·1 0·08 20·5 0·06
DAdiponectin (mg/ml) 9·7 0·71 8·3 0·62
DResistin (ng/ml) 28·0 1·15 23·6 0·62
DLeptin (ng/ml) 11 0·93 4·9 1·09
DGhrelin (pg/ml) 292·6 12·5 2390 23·5
DBFM (kg) 10·1 0·43 6·2 0·79
DBLM (kg) 4·9 1·03 2·8 0·41
DFFM (kg) 5·7 0·55 3·4 0·50
HOMA-IR, homeostasis model assessment-insulin resistance; GH, growth hor-
mone; IGF-1, insulin-like growth factor-1; TSH, thyroid-stimulating hormone;
FT4, free thyroxine; FT3, free tri-iodothyronine; BFM, body fat mass; BLM, body
lean mass; FFM, fat-free mass.
* Mean value was significantly different for AN-R from that of the AN-NR group
(P,0·05; Mann–Whitney U test).












































Fig. 1. (a) Plasma levels of growth hormone (GH) and (b) insulin-like growth
factor-1 (IGF-1) in control subjects (control, ) and in patients with anorexia
nervosa in remission (AN-R, ) and not in remission (AN-NR, ) 6 months
after discharge. At admission (T0), at BMI $16 kg/m2 (T1) and at BMI $17·5 -
kg/m2 (T2). * Mean value was significantly different from that of the control
group (P , 0·05; Mann–Whitney U test). † Mean value was significantly
different from that of the AN-NR group (P , 0·05; Mann–Whitney U test).

















These three parameters explained 88 % of the variance of BMI at
T3 (r 2 0·88; P,0·05), butDGH was the strongest determinant of
BMI at T3, accounting for 74 % of its variability (r 2 0·74; b
20·71; P,0·05).
Discussion
The main original finding of the present study is that GH level
at admission and GH evolution during refeeding may predict
short-term clinical outcome after weight recuperation. Specifi-
cally, low GH levels at admission in hospital and lower ampli-
tude of plasma GH variation between admission and discharge
from hospital were strongly associated with relapse 6 months
after discharge. In addition, GH at admission is an important
contributor in the variability of the final BMI. It is worthy to
note that, despite the small number of patients, clear-cut
differences between remitters and non-remitters were
observed in this particularly homogeneous population charac-
terised by the recent-onset pure restrictive form of AN and
submitted to a standardised inpatient treatment. This finding
should be confirmed by larger and long-term outcome studies.
The prognostic effect of GH variations occurring during
refeeding was independent from concomitant IGF-1 changes
associated with weight gain. Likewise, whereas higher urinary
GH levels have been shown in weight-recovered eumenor-
rhoeic compared with underweight amenorrhoeic and
weight-recovered amenorrhoeic patients, yet, serum IGF-1
levels of amenorrhoeic AN patients were significantly higher
only in weight-recovered but still amenorrhoeic patients
compared with the underweight amenorrhoeic AN patients(12).
The follow-up of the present study was too short to assess the
resumption of menses. Moreover, the impossibility to determine
‘the healthy weight’ corresponding to the weight at the loss of
menstruation could represent a limitation of the study that
might have an impact on its interpretation. We did not observe
any link between the GH level at admission or its evolution
during refeeding and any nutritional behaviour before admis-
sion or psychiatric co-morbidities. High-protein meals as well
as amino acids, such as arginine, lysine, ornithine, tyrosine, gly-
cine and tryptophan, enhance GH release in human subjects(13),
and protein and energy intakes are both essential to regulate
IGF-1(14). The higher GH level in the AN-R group compared
with the AN-NR group at admission cannot be explained by
the nutrients, because we found no difference in energy and
protein intakes between the two groups. The patients did not
receive any medication susceptible to interference with the
GH–IGF-1 axis.
The heterogeneity in GH secretion pattern in patients suffer-
ing from AN had already been noted by Argente et al.(6), and
these authors distinguished two groups characterised by
nycthemeral GH values above or below the threshold of
3 ng/ml for 24 h. However, they were unable to detect any
clinical or psychological feature associated with these pheno-
types. The functional coupling of GH and IGF-1 has been
extensively studied in AN(15,16). The usual pattern associating
low levels of IGF-1, despite an increase of GH secretion,
suggests that AN is characterised by a specific resistance
state to the action of GH. Administration of supraphysiological
recombinant human GH treatment to women with AN does
not overcome this resistance state to GH(17). This resistance
phenomenon is specific to the GH–IGF-1 axis, as the effect
of recombinant human GH on adipose tissue lipolysis is pre-
served as the BFM of the treated patients decreased(17).
Other authors explained the enhanced GH secretion in AN
as a result of an increase in both frequency and amplitude
of secretory pulses(18). These anomalies are totally reversed
after nutritional recovery(6). Brick et al.(19) have shown that
free testosterone could modulate GH secretion across the
weight spectrum: AN, normal weight and obesity.
The mechanism of this peripheral resistance to GH, mainly
at the liver level, is still unknown. Some explanations based
on indirect arguments have been proposed. The decrease in
Table 3. Growth hormone (GH) level in relation to weight (W) at admis-
sion (T0), at BMI reaching 16 kg/m2 (T1) and at discharge (T2) of anor-
exia nervosa (AN) patients in remission (AN-R) and not in remission
(AN-NR)














1 0·60 0·12 0·27 233·2
2 0·77 0·08 0·04 273·5
3 0·84 0·43 0·36 248·4
4 1·08 0·12 0·10 298·3
5 1·11 0·35 0·39 272·1
6 1·29 0·10 0·09 2119·2
Mean 0·95* 0·18† 0·20‡ 274·1*
SEM 0·04 0·01 0·01 5·4
AN-NR (n 5)
1 0·21 0·17 0·15 26·1
2 0·27 0·14 0·13 214·3
3 0·61 0·27 0·24 235·1
4 0·19 0·13 0·17 25·1
5 0·16 0·10 0·14 22·1
Mean 0·28 0·16 0·17 211·2
SEM 0·03 0·01 0·01 2·0
* Mean value was significantly different for AN-R from that of the AN-NR group
(P,0·05; Mann–Whitney U test or Wilcoxon test).
† Mean value was significantly different for the first step of refeeding (T1) from that
of before refeeding (T0) in the AN-R group (P,0·05; Mann–Whitney U test or
Wilcoxon test).
‡ Mean value was significantly different for the second step of refeeding (T2) from
that of before refeeding (T0) in the AN-R group (P,0·05; Mann–Whitney U test
or Wilcoxon test).
§DGH (T2 2 T0) is between admission (T0) and discharge (T2).
Table 4. Individual weight and BMI at admission (admission (baseline)
(T0)) of anorexia nervosa (AN) patients in remission (AN-R) and not in
remission (AN-NR)
(Individual values and mean values with their standard errors)
AN-R (n 6) AN-NR (n 5)
Weight (kg) BMI (kg/m2) Weight (kg) BMI (kg/m2)
34·6 11·4 37·2 13·6
36·5 13·7 39·4 14·5
42·3 13·9 31·0 12·6
36·2 13·5 33·3 11·8
33·5 12·2 38·0 14·1
34·6 13·2
Mean 36·1 13·0 35·7 13·3
SEM 2·1 0·2 2·9 0·1

















the circulating cleaved form of the GH receptor, GH-binding
protein, in malnourished patients suffering from AN suggests
that expression of GH receptor could be decreased in
the target tissues and that this effect is reversible with
refeeding(6,16,20,21). Another hypothesis has recently been pro-
posed attributing a role to the fibroblast growth factor-21
(FGF-21) secreted by the liver(22). Indeed, FGF-21 transgenic
mice are smaller than wild-type littermates and are character-
ised by a profound decrease of IGF-1 without a parallel
decrease of GH secretion(23). As FGF-21 is a hormone secreted
during prolonged starvation in both animals and human sub-
jects, this factor could explain the GH resistance associated
with AN(24). Two studies measuring FGF-21 in this disease
lead to conflicting results. Dostalova et al.(25) observed a
decrease of this factor in patients suffering from AN, with a
subsequent reduction after 2 months of refeeding; however,
it is worthy to note that they found a positive correlation
between the pre-treatment level of FGF-21 and weight gain
during refeeding. Fazeli et al.(22) observed similar FGF-21
levels in AN patients and controls before adjusting for insulin
resistance and BFM; however, after adjustment for these
factors, which could influence FGF-21 production, patients
suffering from AN were characterised by a relative increase
in FGF-21 levels. Moreover, in the Fazeli et al. study, FGF-21
levels were significantly and positively correlated with GH
AUC and negatively with IGF-1 values, suggesting that, as in
rodents, FGF-21 could be a regulator of GH sensitivity in
patients with AN(22). FGF-21 appears to be an important coor-
dinator of the metabolic and hormonal response to prolonged
starvation(24). As IGF-1 and FGF-21 are both primarily pro-
duced in the liver, we looked for any emaciation-induced
liver dysfunctions in the patients characterised by both low
levels of GH at admission and poor prognosis. This hypothesis
can be ruled out, as aminotransferase (alanine aminotransfer-
ase and aspartate aminotransferase) levels at admission were
not different between the patients with or without remission.
We could assume that the increase of GH associated with
active AN could be a marker of the persistence of a correct
FGF-21-mediated adapted response to the disease in some
patients. Refeeding by shutting down the FGF-21 pathway in
these specific patients could lead to a larger weight gain, as
shown by Dostalova et al.(25), and to a better prognosis. In
contrast, paradoxically low levels of GH in acute AN could
be a signal of loss of physiological adaptation associated
with poor prognosis.
In conclusion, monitoring GH levels at admission and
during refeeding in patients suffering from AN has some prog-
nostic value. The role of this factor in the disease is probably
indirect, reflecting specific changes associated with the
adapted response to starvation. Elucidating the pathway of
this response could be useful in improving the care of patients
with AN.
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